Apolipoprotein B particles and cardiovascular disease: a narrative review

This 2023 JAMA Cardiology narrative review is among the most comprehensive of Sniderman’s many statements of the ApoB case — 115 references marshaled to argue that cholesterol-based metrics should yield to particle counting.

The throughline is mechanistic: only ApoB directly reflects the number of atherogenic lipoprotein particles that initiate and propagate atherosclerosis, because each such particle (VLDL, IDL, LDL) carries exactly one ApoB. LDL-C and non-HDL-C estimate cholesterol mass, which varies with particle size and so can mislead — especially when particles are small and cholesterol-poor. The authors integrate genetic, mechanistic, epidemiologic, and outcome evidence toward a single recommendation.

The practical takeaway is to measure ApoB for more precise risk assessment and management, recognizing that traditional cholesterol measures can deceive. The resistance is guideline inertia and the long habit of LDL-C.

We rate the evidence moderate-to-solid: a thorough synthesis of high-quality evidence in a top journal, though narrative in form. Its clinical significance is high — it makes one of the fullest published cases for a paradigm shift in lipid measurement. (Note: this shares its title with the 2019 JAMA Cardiology review in our library; the two are companion statements of the same argument by overlapping author groups.)